ACUTE MYELOID LEUKEMIA COMMITTEE (AML)
Abstract
Outcomes of children with acute myeloid leukemia (AML) have improved significantly in the past decades amongst others by efforts of cooperative groups, an intense collaboration and the coordination of research efforts. The I-BFM AML committee is a working group that unites clinicians, biologists and researchers interested in pediatric acute myeloid disease and/or involved in treatment of patients with acute myeloid malignancies, such as AML and acute promyelocytic leukemia, Down syndrome associated leukemia and myeloproliferative disease. The mission of the I-BFM AML committee is the improvement of outcome and quality of life of children and adolescents with acute myeloid malignancies by promoting and advancing knowledge and exchanging information. The I-BFM AML committee is an interface between the different national and international cooperative groups, the research teams and organizations focused on innovative treatment such as ITCC (Innovative Therapies for Children with Cancer) and EUPAL (EUropean Pediatric Acute Leukemia) initiative.
Scientific aims
- Facilitate and promote the exchange of information between cooperative groups, including preliminary results of clinical trials.
- Support collaborative clinical trials, registries, and initiatives regarding innovation and early phase trials.
- Promote and facilitate collaboration in scientific research projects.
- Stimulate the exchange of discoveries between research groups and between researchers and clinicians.
- Support young investigators working in the field of myeloid malignancies.
Open clinical trials
The I-BFM AML committee is not a sponsor of a clinical trial by itself. The clinical trials listed below are coordinated by cooperative groups and open in 2023:
– ML-DS 2018: for newly diagnosed Down syndrome patients with myeloid leukemia
– AMoRe 2017: for molecular relapsed AML patients
– AIEOP-AML-BFM 2020: frontline protocol (BFM, AIEOP)
– ICC APL study 02: for newly diagnosed APL patients
– NOPHO-DBH AML 2012: frontline protocol (NOPHO DH SHIP)
– MyeChild01: frontline protocol (SFCE, CCLG, Ireland, Australia, Switzerland)
– AAML1831: frontline protocol (COG)
– JPLSG-AML-20: frontline protocol (JCCG)
– JPLSG-AML-P13: for newly diagnosed APL patients (JCCG)
– JPLSG-AML-D16: for newly diagnosed Down syndrome patients with myeloid leukemia (JCCG)
– PedAL trials for relapsed AML patients and early phase trials for relapsed AML (COG)
– EuPAL trials for relapsed AML patients and early phase trials for relapsed AML (ITCC)
Selected Publications
From 2023 onwards:
– van Weelderen RE, Klein K, Harrison CJ, Jiang Y, Abrahamsson J, Arad-Cohen N, Bart-Delabesse E, Buldini B, De Moerloose B, Dworzak MN, Elitzur S, Fernández Navarro JM, Gerbing RB, Goemans BF, de Groot-Kruseman HA, Guest E, Ha S-Y, Hasle H, Kelaidi C, Lapillonne H, Leverger G, Locatelli F, Masetti R, Miyamura T, Norén-Nyström U, Polychronopoulou S, Rasche M, Rubnitz JE, Stary J, Tierens A, Tomizawa D, Zwaan CM, Kaspers GJL. Measurable residual disease and fusion partner independently predict survival and relapse risk in childhood KMT2A-rearranged acute myeloid leukemia: A retrospective study by the I-BFM-SG. J Clin Oncol 2023, in press.
Committee members
Members come from Argentina, Austria, Belgium, Brasil, Canada, Chili, Czech Republic, Denmark, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, The Netherlands, Poland, Portugal, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, United Kingdom, USA
List of cooperative groups:
AIEOP (Italy), BFM Germany, BFM Austria, BFM Slovenia, BSPHO (Belgium), CCLG (UK), COG (USA), CPH (Czech Republic), DCOG (the Netherlands), HeSPHO (Greece), HKPHOSG (Hong Kong), INS (Israel), JPLSG (Japan), SFCE (France), NOPHO (Nordic countries), SEHOP (Spain), SJCRH (USA), SPOG (Switzerland), SSPHO (Switzerland), GPLP (Portugal), PINDA (Chili), PPLLSG (Poland), TPOG (Turkey), SOBOPE (Brasil), HPOG (Hungary).
Acronyms and links of the cooperative groups
